CCL5 and chronic kidney disease: In CKD and dialysis patients, the administration of omega-3 PUFAs can reduce inflammation associated with CKD progression through the upregulation of E- and D-series resolvins [237], together with the reduced level of endothelial chemokines, RANTES, and MCP-1 [238].